Trial Profile
A phase 3, parallel group, randomized, double-blind, placebo controlled multicenter trial to investigate the efficacy, tolerability and safety of fesoterodine sustained release in subjects with overactive bladder syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 May 2019
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer; UCB
- 18 Sep 2006 New trial record.